Lukas Hager's Contact Details

Lukas Hager's Company Details

EntityRisk, Inc.

Princeton, New Jersey, United States • 7 Employees
Information Technology & Services

Biopharmaceuticals are a trillion dollar industry, but buyers and sellers rarely agree on what the "right" price is. Despite an explosion in innovation, regulation and reimbursement remain mired in traditional approaches. -Randomized clinical trials dominate approval and formulary decisions, despite more and better real-world data and new methods to better predict patient responses. -A preoccupation with median response leaves some patients without affordable therapeutic alternatives.-Areas of highest unmet medical need attract significant investments in drugs with the least amount of data at approval and the highest prices.-Financial investors and others who could add liquidity into the market do not have the modeling capabilities to deploy capital with confidence.EntityRisk was founded by three health economists— bringing together decades of academic and industry experience-- to unlock financial innovation in the way new medicines are brought to patients. EntityRisk is building a proprietary algorithmic library to better estimate individual benefits of treatment—through advanced modeling techniques and integrated clinical trial, genomic, and real-world data. Our growing, world-class team of economists, data scientists, software engineers, finance professionals and cutting-edge academic experts is building the tools needed to enable financial innovation in healthcare, some of which include:-Analysis of all current and potential surrogate measures and their connections to critical endpoints of value to patients and payers-Customized individual and subpopulation-level survival and treatment duration curves -Scenario planning for pipeline and inline assets -Proprietary event and cash flow forecasting and analytics for efficacy-linked instruments -Value modeling All of our models are specifically designed to identify risk characteristics and correlations across therapeutic interventions, enabling new value-based payment and performance guarantees.